【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Eubiologics to buy back W6 bln in treasury shares, cancel 75%

온카뱅크관리자

2026-03-11 16:07:30

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="uECiFAyOsv">
 [NA Eun-kyung, Edaily Reporter] Vaccine maker Eubiologics plans to buy back treasury shares worth 6 billion won as part of efforts to enhance shareholder value, the company said Tuesday.
 Eubiologics said in a regulatory filing that it will submit a proposal to approve a treasury share acquisition and disposal plan at its annual general meeting scheduled for March 26. If shareholders approve the proposal, the company will proceed with the buyback program worth a total of 6 billion won.
 The repurchase will be carried out through open market purchases on the KOSDAQ. The acquisition period will be within three months from the date of the shareholder resolution.
 Based on the closing price of 13,290 won on March 4, the trading day prior to the board resolution, the buyback would amount to about 450,000 shares, although the final number may vary depending on the market price at the time of purchase.
 The repurchased shares will be used for cancellation and employee compensation programs such as restricted stock units.
 Eubiologics plans to cancel treasury shares worth about 4.5 billion won, equivalent to roughly 75% of the total shares acquired. Share cancellation reduces the total number of outstanding shares and is expected to increase per-share value, supporting shareholder value over the long term.
 The remaining 1.5 billion won, or about 25%, will be used for employee incentives including restricted stock units. The company said the program aims to strengthen long-term motivation for key employees, attract talent, and build a performance-based compensation system linked to corporate value.
 A company official said the treasury share acquisition is part of efforts to strengthen shareholder return policies.
 “Along with enhancing shareholder value through share cancellation, we will continue to pursue sustainable corporate value growth by securing key talent,” the official said.
 Eubiologics is also accelerating efforts to expand its premium vaccine pipeline based on its capabilities in supplying public vaccines.
 The company is preparing to begin Phase 2 trials for its respiratory syncytial virus vaccine and shingles vaccine, while an Alzheimer’s vaccine candidate is being developed with the goal of entering Phase 1 trials. In cooperation with the Korea Disease Control and Prevention Agency, the company is also developing a Nipah virus vaccine and expanding research on vaccines targeting emerging and reemerging infectious diseases.
 <figure class="figure_frm origin_fig" contents-hash="8ccbd1d41e0bb3dcec635816698fae1f8351681d802a19fed95a949f2d697283" dmcf-pid="8T5w2lpXwE" dmcf-ptype="figure">
 <img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202603/11/Edaily/20260311160512858gcfz.png" data-org-width="554" dmcf-mid="Ufx0kbiPsT" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202603/11/Edaily/20260311160512858gcfz.png" width="658">
 </figure>
 나은경 (eeee@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기